In a report released on December 28, Mark Massaro from BTIG maintained a Hold rating on Ginkgo Bioworks Holdings (DNA – Research Report). The company’s shares closed last Friday at $1.69.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Ginkgo Bioworks Holdings, and MDxHealth S.A. Sponsored ADR. According to TipRanks, Massaro has an average return of -15.6% and a 33.00% success rate on recommended stocks.
Currently, the analyst consensus on Ginkgo Bioworks Holdings is a Hold with an average price target of $3.67.
See the top stocks recommended by analysts >>
DNA market cap is currently $3.58B and has a P/E ratio of -3.78.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ginkgo Bioworks Holdings (DNA) Company Description:
Ginkgo Bioworks Holdings (NYSE:DNA) is a biotechnology company that offers a platform for cell programming that enables the biological production of various products across the food, pharmaceutical, and fragrance industry. Its platform provides equipment, software, robotic automation, and tools to support genetic engineering, analytics, and fermentation.
Read More on DNA:
